A study in Switzerland found an increase in the expected carrier rate of NLRP3 inflammasome gene mutations, which are responsible for the majority of cases of cryopyrin-associated periodic syndrome (CAPS) in PFAPA patients compared to the general population (11). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.